We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




FIT Hemoglobin Predicts Risk of Advanced Neoplasia

By LabMedica International staff writers
Posted on 09 Nov 2017
Print article
Image: The OC-Sensor apparatus used for the quantitative fecal immunochemical test screening for colorectal cancer (Photo courtesy of Eiken).
Image: The OC-Sensor apparatus used for the quantitative fecal immunochemical test screening for colorectal cancer (Photo courtesy of Eiken).
Colorectal cancer (CRC) screening using quantitative fecal immunochemical tests (FITs) is rapidly gaining ground worldwide and FITs are invariably used in a dichotomous manner using pre-specified cut-off values.

Hemoglobin (Hb) concentration in fecal immunochemical test (FIT) results during the first round of colorectal cancer (CRC) screening is an independent predictor of risk of advanced neoplasia (AN) and might be used in designing personalized strategies for CRC screening while reducing unnecessary repeat tests.

Gastroenterologists at the Erasmus MC University Medical Centre (Rotterdam, The Netherlands) analyzed data collected from a population-based study of 9,561 average-risk subjects (50-74 years old) in the Netherlands who were offered four rounds of FIT screening for CRC from November 2006 through December 2014. They analyzed data from 7,663 participants screened at least once and found to have a negative FIT result at baseline (below the cut-off value of 10 μg Hb/ gram of feces [G]). Participants were followed for a median of 4.7 years (interquartile range, 2.0-6.1 years).

The investigators found that participants with two consecutive FIT Hb concentrations equal to or greater than 8 µg/G had a 14-fold increased risk of AN compared to those with baseline concentrations of 0 µg/G. Multi-variate hazard ratios increased from 1.2 for participants with FIT Hb concentrations 0–2 µg/G to 8.2 for those with concentrations 8–10 µg/G. This rising cumulative incidence of AN based on elevated FIT Hb levels was more prominent for Hb concentrations between 4 µg/G and 10 µg/G.

The authors concluded that in a population-based study of average-risk individuals with a FIT result below the cut-off value,they associated baseline concentrations of 8-10 μg fecal Hb/G with an increased risk of AN compared with baseline concentrations of 0 μg fecal Hb/G. Baseline and consecutive fecal Hb concentrations are independent predictors for incident AN. This information might be used in designing personalized strategies for population-based CRC screening and reduce unnecessary repeat tests. The study was originally published on July 28, 2017, in the journal Gastroenterology.

Related Links:
Erasmus MC University Medical Centre

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.